Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Search Results

Now showing 1 - 2 of 2
  • Item
    Interexaminer Reproducibility of Optical Coherence Tomography for Measuring the Tear Film Meniscus
    (2014) Canan, Handan; Altan-Yaycioglu, Rana; Ulas, Burak; Sizmaz, Selcuk; Coban-Karatas, Muge; https://orcid.org/0000-0002-5877-6536; https://orcid.org/0000-0002-9139-8848; 24749829; AAB-6394-2021; AAG-3306-2019
    Purpose: New optical coherence tomography (OCT) devices with anterior segment module are able to measure the tear meniscus height (TMH) and tear meniscus area (TMA). Since the borders of the area and the height are to be marked by an examiner, the measurements are prone to be subjective. Herein, we aimed to evaluate the interexaminer reproducibility of the tear meniscus measurements with OCT. Materials and Methods: In this prospective cross-sectional study, both eyes of 300 consecutive patients with and without dry eye were studied. Following routine ophthalmologic examination, tear-film OCT images were obtained. Two examiners, who were unaware of the other examiner's results, measured the TMH (i. e. the line connecting the intersection of the meniscus with the cornea/sclera and eyelid) and cross-sectional TMA. The reliability and correlation of the two examiners' results were assessed. Results: Four right and six left eyes were excluded from the final analysis, so a total of 590 eyes were evaluated. The mean difference of the two examiners' measurements of both eyes was - 0.001 +/- 0.027mm(2) in TMA, and - 21.29 +/- 39.95 mm in TMH. An agreement between the two examiners was found regarding TMA and TMH measurements for right and left, as well as both eyes (Cronbach's alpha > 0.900, for all). Also, the correlation between both variables was high (inter item correlation matrix > 0.840, for all). Conclusions: We showed a strong statistical agreement for both TMA and TMH measurements. According to our results, we believe that FD-OCT device is dependable in measuring the TMA and TMH values, given that its results are reproducible.
  • Thumbnail Image
    Item
    Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion
    (2016) Coban-Karatas, Muge; Altan-Yaycioglu, Rana; Ulas, Burak; Sizmaz, Selcuk; Canan, Handan; Sarıtürk, Cagla; 27275430
    AIM: To evaluate central macular thickness (CMT) and mean choroidal thickness (MCT) in eyes with branch retinal vein occlusion (BRVO), before and after ranibizumab treatment using spectral domain -optical coherence tomography (SD-OCT). METHODS: Forty -two patients with unilateral BRVO and macular edema were included in this study. There were 25 men and 17 women. Using SD-OCT, choroidal thickness was measured at 500 mu m intervals up to 1500 mu m temporal and nasal to the fovea. MCT was calculated based on the average of the 7 locations. All the eyes with BRVO were treated with intravitreal ranibizumab (0.5 mg/0.05 mL). Comparisons between the BRVO and fellow eyes were analyzed using Mann-Whitney test. Pre-injection and post-injection measurements were analyzed using Wilcoxon test and repeated measure analysis. RESULTS: At baseline, there was a significant difference between the BRVO and fellow eyes in MCT [BRVO eyes 245 (165-330) mu m, fellow eyes 229 (157-327) mu m] and CMT [BRVO eyes 463 (266-899) mu m, fellow eyes 235 (148-378) mu m (P=0.041, 0.0001, respectively)]. Following treatment, CMT [295 (141-558) mu m] and MCT [229 (157329) mu m] decreased significantly compared to the baseline measurements (P=0.001, 0.006, respectively). Also BCVA (logMAR) improved significantly (P=0.0001) in the BRVO eyes following treatment. After treatment CMT [BRVO eyes 295 (141-558) mu m, fellow eyes 234 (157-351) mu m] and MCT [BRVO eyes 229 (157-329) mu m, fellow eyes 233 (162-286) mu m] values did not reveal any significant difference in BRVO eyes and fellow eyes (P=0.051, 0.824, respectively). CONCLUSION: In eyes with BRVO, CMT and MCT values are greater than the fellow eyes, and decrease significantly following ranibizumab injection.